SAB Biotherapeutics heads into its May 12 Q1 print with options positioning making a dramatic U-turn — and a hantavirus catalyst generating fresh trader attention.
The starkest move in the setup is in the options market. The put/call ratio collapsed to 0.39 on May 8, well over one and a half standard deviations below its 20-day average of 2.48. For most of April, SABS options carried heavy downside protection — the PCR ran above 3.0 for nearly three straight weeks. That wall of puts has been replaced almost overnight by a pronounced call-heavy tilt, the lowest defensive reading in a year. The trigger appears to be circulating analyst commentary, reported on May 8, suggesting the company's SAB-163 antibody programme is the most advanced antibody-based hantavirus countermeasure in development — a biosecurity angle that adds a distinct catalyst layer to an otherwise diabetes-focused story.
Short interest tells a more cautious structural story, even as the options crowd turns bullish. Short interest has climbed 64% over the past month to 6.4% of the free float, crossing a threshold where it warrants genuine attention. Bears have been adding steadily since mid-April. Borrowing costs, at roughly 28.6% annualised, remain elevated even after easing about 21% on the week — suggesting the shorts who are in have paid a significant carry cost to get there. Availability is moderate, meaning the borrow market is not at a breaking point, but it is not wide open either. The ORTEX short score of 74.1 places SABS in the top decile for short pressure across the universe.
The analyst community is uniformly bullish in direction, though targets diverge meaningfully. The most recent action — from March 2026 — saw Chardan Capital raise its target to $14 while HC Wainwright trimmed to $7, both keeping Buy ratings. The stock at $4.11 trades well below even the more conservative targets, implying substantial upside in the bull case. Bulls point to the unique platform approach to Type 1 Diabetes, positive clinical data and patent protection. Bears focus on the absence of meaningful patient-scale data, a history of losses and the brutal competitive dynamics in immunology and metabolic disease. A cluster of specialist biotech funds — including Millennium Management, which filed a new 13G in May, and Perceptive Advisors — have built meaningful recent positions, lending some institutional credibility to the bull case.
Past earnings reactions have swung hard in both directions. The November 2025 print produced a one-day gain of 12.9% and a five-day move of over 27%. The March 2026 report saw an 8.2% jump on the day. The one exception was a small loss on March 30, following an announcement made months earlier. The asymmetry skews toward upside reactions, though the sample is small and pre-announcement dynamics matter here. Monday's print is ultimately a test of whether the hantavirus narrative has real clinical and commercial substance — and whether the diabetes programme's data can match the implied upside embedded in a stock that still trades at less than half of even the most conservative analyst targets.
See the live data behind this article on ORTEX.
Open SABS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
